TNXP
Tonix Pharma (TNXP) Fair Value Raised to $12 at Janney Capital
June 29, 2015 6:55 AM
Janney Capital analyst Chiara Russo reiterated a Buy rating and adjusted its fair value target on Tonix Pharma (NASDAQ: TNXP) to $12.00 (from $10.00), saying non-clinical study supports TNX-201 in headache.
Russon commented, "We spent some time with Tonix CEO Seth Lederman this week following their poster presentations at the Annual Scientific Meeting of the American Headache Society. Though non-clinical in nature, one poster in particular caught our eye as it supports the development of TNX-201 in tension headache as the isolated (R)-isomer of isometheptene decreased trigeminal (cranial nerve) pain in not one, but two established rat models."
